Aug 26, 2026, 17:13
Kemal Karaagac: NOACs May Offer Cognitive and Clinical Benefits in AF With Alzheimer’s Disease
Kemal Karaagac, Cardiologist at Cihangir Hospital, shared a post on X about a recent article by Nanbo Zhu et al., published in European Heart Journal, adding:
”In patients with AF and AD, NOAC use was associated with modestly slower cognitive decline and more favourable effectiveness and safety profiles, compared to warfarin or no anticoagulation.”
Title: Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer’s disease: a Swedish nationwide study
Authors: Nanbo Zhu, Hong Xu, Sara Garcia-Ptacek, Sumonto Mitra, Maria Eriksdotter
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 24, 2026, 12:56Maria Helena Parrinello: A New Score for Chronic GvHD Risk Assessment at the SIE Congress
-
Sep 24, 2026, 12:44Shehab Mohamed: TP53 Mutations and Outcomes in Myeloproliferative Neoplasms
-
Sep 24, 2026, 12:34Francesca Palandri: Is There Still a Place for Splenectomy in ITP in the Modern Era?
-
Sep 24, 2026, 12:15Cedric Hermans: RPTH Illustrated Review on Von Willebrand Disease
-
Sep 24, 2026, 11:48Factor XII Inhibition and the Future of Contact Pathway Targeting
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure
-
Sep 24, 2026, 06:33Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access